These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 24050442

  • 1. Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors.
    Xue X, Wei JL, Xu LL, Xi MY, Xu XL, Liu F, Guo XK, Wang L, Zhang XJ, Zhang MY, Lu MC, Sun HP, You QD.
    J Chem Inf Model; 2013 Oct 28; 53(10):2715-29. PubMed ID: 24050442
    [Abstract] [Full Text] [Related]

  • 2. An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors.
    Xue X, Bao G, Zhang HQ, Zhao NY, Sun Y, Zhang Y, Wang XL.
    Molecules; 2018 Dec 01; 23(12):. PubMed ID: 30513790
    [Abstract] [Full Text] [Related]

  • 3. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H, Chemi G, Campiani G, Brogi S.
    Comput Biol Chem; 2019 Dec 01; 83():107105. PubMed ID: 31473433
    [Abstract] [Full Text] [Related]

  • 4. Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction.
    Jacoby E, Boettcher A, Mayr LM, Brown N, Jenkins JL, Kallen J, Engeloch C, Schopfer U, Furet P, Masuya K, Lisztwan J.
    Methods Mol Biol; 2009 Dec 01; 575():173-94. PubMed ID: 19727615
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors.
    Tortorella P, Laghezza A, Durante M, Gomez-Monterrey I, Bertamino A, Campiglia P, Loiodice F, Daniele S, Martini C, Agamennone M.
    J Chem Inf Model; 2016 Jun 27; 56(6):1216-27. PubMed ID: 27269808
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
    Dezi C, Carotti A, Magnani M, Baroni M, Padova A, Cruciani G, Macchiarulo A, Pellicciari R.
    J Chem Inf Model; 2010 Aug 23; 50(8):1451-65. PubMed ID: 20726601
    [Abstract] [Full Text] [Related]

  • 9. Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.
    Gessier F, Kallen J, Jacoby E, Chène P, Stachyra-Valat T, Ruetz S, Jeay S, Holzer P, Masuya K, Furet P.
    Bioorg Med Chem Lett; 2015 Sep 01; 25(17):3621-5. PubMed ID: 26141769
    [Abstract] [Full Text] [Related]

  • 10. Prospective virtual screening for novel p53-MDM2 inhibitors using ultrafast shape recognition.
    Patil SP, Ballester PJ, Kerezsi CR.
    J Comput Aided Mol Des; 2014 Feb 01; 28(2):89-97. PubMed ID: 24554192
    [Abstract] [Full Text] [Related]

  • 11. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
    Golestanian S, Sharifi A, Popowicz GM, Azizian H, Foroumadi A, Szwagierczak A, Holak TA, Amanlou M.
    Life Sci; 2016 Jan 15; 145():240-6. PubMed ID: 26746660
    [Abstract] [Full Text] [Related]

  • 12. Constructing an atomic-resolution model of human P2X7 receptor followed by pharmacophore modeling to identify potential inhibitors.
    Ahmadi M, Nowroozi A, Shahlaei M.
    J Mol Graph Model; 2015 Sep 15; 61():243-61. PubMed ID: 26298810
    [Abstract] [Full Text] [Related]

  • 13. Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies.
    Bandaru S, Ponnala D, Lakkaraju C, Bhukya CK, Shaheen U, Nayarisseri A.
    Asian Pac J Cancer Prev; 2015 Sep 15; 16(9):3759-65. PubMed ID: 25987034
    [Abstract] [Full Text] [Related]

  • 14. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.
    Zaytsev A, Dodd B, Magnani M, Ghiron C, Golding BT, Griffin RJ, Liu J, Lu X, Micco I, Newell DR, Padova A, Robertson G, Lunec J, Hardcastle IR.
    Chem Biol Drug Des; 2015 Aug 15; 86(2):180-9. PubMed ID: 25388787
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
    Atatreh N, Ghattas MA, Bardaweel SK, Rawashdeh SA, Sorkhy MA.
    Drug Des Devel Ther; 2018 Aug 15; 12():3741-3752. PubMed ID: 30464405
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
    Zhao Y, Aguilar A, Bernard D, Wang S.
    J Med Chem; 2015 Feb 12; 58(3):1038-52. PubMed ID: 25396320
    [Abstract] [Full Text] [Related]

  • 20. Discovery of novel tubulin inhibitors via structure-based hierarchical virtual screening.
    Cao R, Liu M, Yin M, Liu Q, Wang Y, Huang N.
    J Chem Inf Model; 2012 Oct 22; 52(10):2730-40. PubMed ID: 22992059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.